 |
12/17/2007
PTC THERAPEUTICS PRESENTS ENCOURAGING PHASE 1 RESULTS OF ITS NOVEL VEGF INHIBITOR, PTC299, AT 30TH ANNUAL SAN ANTONIO BREAST CANCER SYMPOSIUM
|
12.4 KB |
| |
SAN ANTONIO and SOUTH PLAINFIELD, N.J., Dec 17, 2007 /PRNewswire via COMTEX News Network/ -- PTC Therapeutics, Inc. (PTC), a biopharmaceutical company focused on the discovery, development, and commercialization of small-molecule drugs targeting post-transcriptional control mechanisms announced the presentation of preclinical and Phase 1 data regar...
|
|
12/06/2007
PTC THERAPEUTICS ANNOUNCES ADDITIONAL $1.6 MILLION GRANT FROM THE SPINAL MUSCULAR ATROPHY FOUNDATION
|
9.6 KB |
| |
SOUTH PLAINFIELD, N.J., Dec 06, 2007 /PRNewswire via COMTEX News Network/ -- PTC Therapeutics, Inc. (PTC), a biopharmaceutical company focused on the discovery, development, and commercialization of small-molecule drugs targeting post-transcriptional control mechanisms, today announced an expanded research collaboration with the Spinal Muscular Atr...
|
|
10/18/2007
PTC THERAPEUTICS ANNOUNCES ADDITIONAL RESULTS FROM PHASE 2 STUDY OF PTC124 IN DUCHENNE MUSCULAR DYSTROPHY
|
12.4 KB |
| |
SOUTH PLAINFIELD, N.J., Oct 18, 2007 /PRNewswire via COMTEX News Network/ -- PTC Therapeutics, Inc. (PTC), a biopharmaceutical company focused on the discovery, development, and commercialization of small-molecule drugs targeting post-transcriptional control mechanisms, today announced additional data from a Phase 2 clinical trial of PTC124 in pati...
|
|
10/11/2007
PTC THERAPEUTICS ANNOUNCES PHARMACOKINETIC AND SAFETY RESULTS FROM PHASE 2 STUDY OF PTC124 IN DUCHENNE MUSCULAR DYSTROPHY
|
11.4 KB |
| |
SOUTH PLAINFIELD, N.J., Oct 11, 2007 /PRNewswire via COMTEX News Network/ -- PTC Therapeutics, Inc. (PTC), a biopharmaceutical company focused on the discovery, development and commercialization of small-molecule drugs targeting post-transcriptional control mechanisms, today announced pharmacokinetic and safety data from a Phase 2 clinical trial of...
|
|
10/05/2007
PTC THERAPEUTICS ANNOUNCES ENCOURAGING ADDITIONAL PHASE 2 RESULTS OF PTC124 IN CYSTIC FIBROSIS
|
13.0 KB |
| |
SOUTH PLAINFIELD, N.J., Oct 05, 2007 /PRNewswire via COMTEX News Network/ -- PTC Therapeutics, Inc. (PTC), a biopharmaceutical company focused on the discovery, development and commercialization of small-molecule drugs targeting post-transcriptional control mechanisms, today announced encouraging data from a Phase 2 clinical trial of PTC124 in ped...
|
|
09/13/2007
PTC THERAPEUTICS ANNOUNCES $20 MILLION STRATEGIC INVESTMENT FROM CELGENE CORPORATION
|
8.8 KB |
| |
SOUTH PLAINFIELD, N.J., Sept 13, 2007 /PRNewswire via COMTEX News Network/ -- PTC Therapeutics, Inc. (PTC), a biopharmaceutical company focused on the discovery, development and commercialization of small-molecule drugs targeting post-transcriptional control mechanisms, today announced that that Celgene Corporation (Nasdaq: CELG) will make a $20 mi...
|
|
08/02/2007
PTC THERAPEUTICS APPOINTS THERESA NATALICCHIO AS SENIOR VICE PRESIDENT OF MARKETING AND SALES
|
8.8 KB |
| |
SOUTH PLAINFIELD, N.J., Aug 02, 2007 /PRNewswire via COMTEX News Network/ -- PTC Therapeutics, Inc. (PTC), a biopharmaceutical company focused on the discovery, development and commercialization of small-molecule drugs targeting post-transcriptional control mechanisms, today announced that Theresa Natalicchio has been appointed as Senior Vice Presi...
|
|
07/10/2007
PTC THERAPEUTICS ANNOUNCES $15.4 MILLION NIH RESEARCH GRANT FOR DUCHENNE MUSCULAR DYSTROPHY
|
12.5 KB |
| |
SOUTH PLAINFIELD, N.J., July 10, 2007 /PRNewswire-USNewswire via COMTEX News Network/ -- PTC Therapeutics, Inc. (PTC), a biopharmaceutical company focused on the discovery, development and commercialization of small-molecule drugs targeting post-transcriptional control mechanisms, today announced that the National Institute of Neurological Disorder...
|
|
06/26/2007
PTC THERAPEUTICS APPOINTS MANAL MORSY, M.D., PH.D. AS VICE PRESIDENT OF REGULATORY AFFAIRS
|
8.7 KB |
| |
SOUTH PLAINFIELD, N.J., June 26, 2007 /PRNewswire via COMTEX News Network/ -- PTC Therapeutics, Inc. (PTC), a biopharmaceutical company focused on the discovery, development and commercialization of small-molecule drugs targeting post-transcriptional control mechanisms, today announced the appointment of Manal Morsy, M.D., Ph.D. as Vice President o...
|
|
06/03/2007
PTC THERAPEUTICS PRESENTS PHASE 1 RESULTS OF ITS NOVEL VEGF INHIBITOR, PTC299, AT 43RD AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING
|
12.1 KB |
| |
CHICAGO and SOUTH PLAINFIELD, N.J., June 3, 2007 /PRNewswire via COMTEX News Network/ -- PTC Therapeutics, Inc. (PTC), a biopharmaceutical company focused on the discovery and development of small-molecule drugs targeting post-transcriptional control mechanisms, today presented data from its Phase 1 single- and multiple-dose studies in healthy volu...
|
|
05/04/2007
PTC THERAPEUTICS ANNOUNCES ADDITIONAL POSITIVE INTERIM PHASE 2 RESULTS OF PTC124 IN DUCHENNE MUSCULAR DYSTROPHY
|
13.2 KB |
| |
BOSTON and SOUTH PLAINFIELD, N.J., May 4, 2007 /PRNewswire via COMTEX News Network/ -- PTC Therapeutics, Inc. (PTC), a biopharmaceutical company focused on the discovery and development of small-molecule drugs targeting post-transcriptional control processes, today announced positive interim data from a Phase 2 clinical trial of PTC124 in patients ...
|
|
05/02/2007
PTC THERAPEUTICS ANNOUNCES PROMOTION OF NEIL ALMSTEAD TO SENIOR VICE PRESIDENT OF CHEMISTRY AND CMC
|
8.5 KB |
| |
SOUTH PLAINFIELD, N.J., May 2, 2007 /PRNewswire via COMTEX News Network/ -- PTC Therapeutics, Inc. (PTC), a biopharmaceutical company focused on the discovery and development of orally administered, proprietary small-molecule drugs that target post- transcriptional control processes, today announced the promotion of Neil Almstead to Senior Vice Pre...
|
|
04/23/2007
TARGETING SPECIFIC MUTATIONS REVEALS PROMISING NEW APPROACH TO TREATING GENETIC DISORDERS; PRECLINICAL DATA PUBLISHED IN NATURE
|
11.0 KB |
| |
SOUTH PLAINFIELD, N.J., April 23, 2007 /PRNewswire via COMTEX News Network/ -- New preclinical data published online in the current edition of the journal Nature show that PTC124, an investigational new drug designed to bypass nonsense mutations, was efficacious in a preclinical model of Duchenne muscular dystrophy (DMD). It is estimated that appro...
|
|
04/20/2007
PTC THERAPEUTICS WITHDRAWS IPO REGISTRATION STATEMENT
|
8.1 KB |
| |
SOUTH PLAINFIELD, N.J., April 20, 2007 /PRNewswire via COMTEX News Network/ -- PTC Therapeutics, Inc., announced today that it has withdrawn its S-1 registration statement, previously filed with the Securities and Exchange Commission (SEC).
(Logo: http://www.newscom.com/cgi-bin/prnh/20010919/PTCLOGO )
"Since we originally filed our S-1 last...
|
|
01/08/2007
PTC THERAPEUTICS ANNOUNCES STRATEGIC DRUG DISCOVERY COLLABORATION WITH PFIZER UTILIZING PTC'S GEMS TECHNOLOGY PLATFORM
|
7.1 KB |
| |
SOUTH PLAINFIELD, N.J., January 8, 2007 – PTC Therapeutics, Inc (PTC) announced today an exclusive research collaboration and licensing agreement with Pfizer Inc for the development of pharmaceuticals through the application of PTC's GEMS (Gene Expression Modulation by Small-molecules) technology. Under the terms of the agreement Pfizer has m...
|
| Showing 1-15 of 15 |
Page: 1 |
|
|